Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence

Jana Luetzkendorf, Lutz P. Mueller, Thomas Mueller, Henrike Caysa, Katrin Nerger, Hans-Joachim Schmoll

Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle, Germany

Received: January 19, 2009; Accepted: May 13, 2009

Abstract

Colorectal carcinoma (CRC) constitutes a common malignancy with limited therapeutic options in metastasized stages. Mesenchymal stem cells (MSC) home to tumours and may therefore serve as a novel therapeutic tool for intratumoral delivery of antineoplastic factors. Tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) which promises apoptosis induction preferentially in tumour cells represents such a factor. We generated TRAIL-MSC by transduction of human MSC with a third generation lentiviral vector system and analysed their characteristics and capacity to inhibit CRC growth. (1) TRAIL-MSC showed stable transgene expression with neither changes in the defining MSC characteristics nor signs of malignant transformation. (2) Upon direct in vitro coculture TRAIL-MSC induced apoptosis in TRAIL-sensitive CRC-cell lines (DLD-1 and HCT-15) but also in CRC-cell lines resistant to soluble TRAIL (HCT-8 and SW480). (3) In mixed subcutaneous (s.c.) xenografts TRAIL-MSC inhibited CRC-tumour growth presumably by apoptosis induction but a substantial proportion of TRAIL-MSC within the total tumour cell number was needed to yield such anti-tumour effect. (4) Systemic application of TRAIL-MSC had no effect on the growth of s.c. DLD-1 xenografts which appeared to be due to a pulmonary entrapment and low rate of tumour integration of TRAIL-MSC. Systemic TRAIL-MSC caused no toxicity in this model. (5) Wild-type MSC seemed to exert a tumour growth-supporting effect in mixed s.c. DLD-1 xenografts. These novel results support the idea that lentiviral TRAIL-transgenic human MSC may serve as vehicles for clinical tumour therapy but also highlight the need for further investigations to improve tumour integration of transgenic MSC and to clarify a potential tumour-supporting effect by MSC.

Keywords: MSC • TRAIL • gene therapy • lentiviral • resistance • colorectal carcinoma

Introduction

Treatment options for metastasized colorectal carcinoma (CRC) after standard therapy are limited [1]. A promising new approach for an efficient tumour therapy comprises the use of stem cells as vehicles for the expression of tumour-inhibiting factors as in animal models an integration of stem cells into malignant tumours has been demonstrated [2–4]. A candidate for such an approach are mesenchymal stem cells (MSC) which can be easily obtained from adult tissues and are defined by standard criteria [5]. In xenograft models, transgenic MSC were shown to suppress tumour growth through ectopic expression of pro-apoptotic genes like interferon-β [6] or genes encoding enzymes activating anti-neoplastic prodrugs [7]. Specifically for CRC, such integration as well as an anti-tumour activity of transgenic MSC has been shown in animal models [7, 8].

The clinical application of transgenic MSC for tumour therapy requires (i) a transplantation approach without the need for subsequent immunosuppression; (ii) a safe and efficient expression of a transgene with high anti-tumour activity and little toxicity and (iii) an efficient and specific tumour integration of MSC.

The immunogenicity of MSC is a matter of debate [9] and an allogeneic setting still bears an undefined risk of rejection. We have previously shown that MSC can be derived from the bone marrow after extensive chemotherapeutic treatment [10]. Thus the
clinical use of autologous MSC from patients treated with chemotherapy is feasible and does not entail the risk of immunorejection.

A candidate for a potent anti-tumour transgene is Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) which induces apoptosis through binding on death receptors (DR) leading to activation of the extrinsic apoptosis pathway via caspase-8. Generally, tumour cells show a higher sensitivity for TRAIL-induced apoptosis presumably due to a higher expression of death receptors in tumour cells and expression of decoy receptors in non-malignant cells [11]. Clinical trials with TRAIL or DR agonists are currently performed including patients with CRC [12]. However, in vitro studies demonstrate a resistance of some CRC-cell lines for soluble TRAIL and the known TRAIL sensitivity of selected agonists are currently performed including patients with CRC [11]. Therefore, our study supports the use of transgenic MSC for tumour therapy but also demonstrates the need for further studies before clinical applications can be ventured.

Material and methods

MSC, cell lines and cell culture

Cultivation as well as analysis of growth kinetics and differentiation of MSC isolated from human bone marrow according to a protocol approved by the institutional Ethics Board were performed as described previously [10] with the following modifications. Growth medium was composed of DMEM (low glucose, PAA, Pasching, Austria), 15% foetal calf serum (FCS) selected for optimal growth (Invitrogen, Grand Island, NY, USA) and 1% penicillin/streptomycin (PAA). For differentiation induction osteogenic medium (DMEM/10% FCS, 200 μM ascorbic acid 2-phosphate, 50 μM dexamethasone, 10 mM glyceral-3-phosphate) and adipogenic medium (DMEM/10% FCS, 10 μg/ml insulin, 100 μM indomethacin, 500 μM 3-isobuty1-1-methylxanthine, 50 μM dexamethasone, 5 μM rosiglitazone) (Sigma-Aldrich, St. Louis, MO, USA) were used. Treatment with soluble TRAIL was performed for 24 hrs with 100 ng/ml soluble KillerTRAIL (Axxora, San Diego, CA, USA) in growth medium. Dil (Invitrogen) labelling was performed at 2.5 μM in growth medium for 24 hrs immediately before transplantation.

The human CRC-cell lines HCT-8, HCT-15, DLD-1 and SW480 were cultivated in RPMI-1640 (PAA) with 10% FCS and 1% penicillin/streptomycin. Human embryonic kidney (HEK) 293T cells were cultivated in DMEM with 15% FCS and 1% penicillin/streptomycin.

Screening for TRAIL sensitivity of CRC-cell lines

Sensitivity of CRC-cell lines to soluble TRAIL was estimated by a sulforhodamine-B-assy according to established protocols [23]. CRC-cell lines were seeded at 5000 cells/well in three 96-well plates with eight wells per cell line on each plate, respectively. After 48 hrs one plate was fixed with 10% trichloroacetic acid (‘control 24 hrs’) and one plate treated with 100 ng/ml soluble KillerTRAIL for 24 hrs (‘soluble TRAIL 24 hrs’). After 24 hrs the two treated plates were fixed with 10% trichloroacetic acid. Fixed plates were stained with 0.4% sulforhodamine-B as described [23]. Optical density (570 nm) was determined in a microplate reader and the mean of the eight wells for each cell line at the respective condition was calculated. Values from ‘control 0 hr’ were set 100% and compared to ‘control 24 hrs’ and ‘soluble TRAIL 24 hrs’.

Plasmid constructs

Human TRAIL-cDNA was obtained from Jurkat-cell-RNA by RT-PCR using the primers 5’-AACAGGGCTTACGACGACC and 5’-ATGAGCCACAATTAAGGGCC. The resulting cDNA covered bps 26–935 of human TRAIL-mRNA (NCBI accession no. U37518). TRAIL-cDNA was incorporated into pCR2.1-TOPO (Invitrogen), a TRAIL-containing EcoRI fragment was generated and the recessed ends were blunt-ended with Klenow enzyme.

From the transfer vector plasmid pFUGW [24] GFP was removed by BanHI, EcoRI digestion. The recessed ends of the pFUGW backbone were blunt-ended and ligated with the blunt-ended TRAIL fragment. Insert direction and sequence fidelity of the resulting TRAIL-encoding transfer vector plasmid pFUTW were proven by sequencing.

DsRed-cDNA was obtained by PCR from pDsRed2-N1 (Clontech, Mountain View, CA, USA) with the primers 5’-GCCACCGGATCCACGCTCC and 5’-CCACGGAATTCTGGCTACAGGAA. The cDNA was cleaved with BanHI and EcoRI and ligated into the BanHI-EcoRI-fragment of pFUGW yielding the DsRed-encoding transfer vector plasmid pFUDW.

For lentiviral vector production the packaging plasmids pMDLg/pRRE and pRSV-Rev [22] and the envelope plasmid pSVG were used. The plasmids pMDLg/pRRE, pRSV-Rev, pSVG and pFUGW were kindly provided by Prof. Dr. T. Braun, Max-Planck-Institut für Herz- und Lungenforschung, Bad Nauheim.

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Vector production and transduction of cells

Vector particles were produced by transient transfection of HEK293T cells with 10 μg transfer vector plasmid and 5 μg of pMDLg/pRRE, pRSV-Rev and pVSVG, respectively, by calcium phosphate DNA precipitation. After 48 hrs the vector containing supernatant was harvested, concentrated by ultracentrifugation and titrated on HEK293T cells.

For transduction, cells were grown to 50% confluence and fed with fresh growth medium containing 8 μg/ml polybrene (Sigma-Aldrich). Transduction of MSC was performed at passage 1 or 2. Titres used for transduction were about 5 × 10^10 viral particles/ml. Medium was replaced after 24 hrs and the transgene expression was analysed after additional 24 hrs. Untransduced WT-MSC served as controls in the subsequent experiments.

Flow cytometry

Flow cytometry was performed as described previously [10]. MSC were labelled with the following mouse anti-human antibodies: Simultest Control yH/yL, anti-CD14-FITC, anti-CD45-PE, anti-HLA-DR-FITC, anti-CD19-PE, labelled with the following mouse anti-human antibodies: Simultest Control yH/yL, anti-CD14-FITC, anti-CD45-PE, anti-HLA-DR-FITC, anti-CD19-PE, anti-CD90-PE, anti-CD73-PE (BD Biosciences, Franklin Lakes, NJ, USA) and anti-CD105-FITC (Serotec, Oxford, UK).

Flow cytometry

For annexin V-staining the Annexin V-FITC Apoptosis detection kit I (BD Biosciences) was used according to manufacturer's instructions. All analyses were performed on a FACSCalibur using CellQuest software (all BD Biosciences).

Immunocytochemistry

Cells were cultivated in chamber slides and fixed with methanol/acetone (1:1) or 2% formalin. The primary mouse antibodies – control IgG1 (AnCell Corporation, Bayport, MN, USA), anti-TRAIL clone 2E5 (Axxora) on methanol/acetone-fixed slides and anti-TRAIL clone ZZ02 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) on formalin-fixed slides – were used at 10 μg/ml over night. After washing, seeds were incubated with 5 μg/ml IRDye800-conjugated goat antimmouse IgG (Li-COR Biosciences, Lincoln, NE, USA) for 1 hr. Subsequently, slides were exposed to 1 μg/ml DAPI (Sigma-Aldrich) for counterstaining of nuclei, covered with fluorescence mounting medium and analysed on a Nikon Eclipse TE2000-E (Nikon, Düsseldorf, Germany). All procedures were performed at room temperature.

Coculture experiments

TRAIL-MSC or WT-MSC (10,000 cells/cm^2, respectively) were mixed with DsRed-DLD-1 cells (50,000 cells/cm^2) or DsRed-HCT-8 cells (60,000 cells/cm^2) and plated on 12-well plates. After 24 hrs detached cells were harvested, counted and analysed for annexin V-staining. Adherent cells from one well were harvested, counted and analysed by flow cytometry for DsRed expression. This procedure was repeated 48 hrs and 72 hrs after initial plating. The TRAIL-neutralizing antibody (clone 2E5) was used at a concentration of 10 μg/ml.

Lysates of whole coculture (i.e. all adherent and detached cells) and lysates from detached cells only were prepared from separate wells after 24 hrs cocultivation of CRC cells (DLD-1 50,000 cells/cm^2, HCT-8 60,000 cells/cm^2, HCT-15 and SW480 each 100,000 cells/cm^2) with WT-MSC and with TRAIL-MSC (each 10,000 cells/cm^2, respectively).

Western blotting

Western blot analyses were performed as described previously [10] using the following primary mouse antibodies: anti-caspase-3 (0.5 μg/ml, MBL, Woburn, MA, USA), anti-caspase-8 (0.5 μg/ml, Invitrogen), anti-poly (ADP-ribose) polymerase (PARP) (1 μg/ml, BD Biosciences), anti-TRAIL (0.5 μg/ml, clone HSS01, Axxora) and anti-tubulin (0.1 μg/ml, Dianova, Hamburg, Germany). Immunocomplexes were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, Little Chalfont, England) using horseradish peroxidase-conjugated antimmouse IgG (0.1 μg/ml, Santa Cruz Biotechnology) and Roti-Lumin (Carl Roth, Karlsruhe, Germany).

Animal studies

Six- to 8-week-old athymic nude-fox n1 nu/nu mice (Harlan Winkelmann, Borchen, Germany) were used for the in vivo experiments according to institutional guidelines under approved protocols.

Subcutaneous (s.c.) mixed xenografts were generated as follows: 3 × 10^6 DsRed-CRC cells per tumour were mixed with TRAIL-MSC or with control MSC (GFP- or WT-MSC) and administered into the right (TRAIL-MSC) and the left (control MSC) flank of one animal. The following proportions of MSC were used in mixed xenografts: 7.5 × 10^4 (i.e. 20% of total injected cell number), 3.33 × 10^5 (10%), 9.3 × 10^4 (3%) and 3.03 × 10^5 (1%). Tumour growth was determined over 17 days by fluorescence imaging. Animals were killed and dissected tumours were embedded in paraffin.

For studying the effects of systemically applied MSC 5 × 10^6 GFP-DLD-1 cells were injected s.c. into the left flank of one animal. 2.25 × 10^6 Dil-labelled TRAIL- (treatment) or WT-MSC (cell control) or a respective volume of PBS (control) were administered into tail vein after 2, 4, 7, 10 and 15 days. Tumour growth was determined over 18 days by fluorescence imaging. After killing of animals, lungs and s.c. tumours were dissected and cryosections were prepared.

Every experiment was done at least in triplicates. None of the animals had to be killed prematurely due to tumour burden or impaired vital parameters.

Image acquisition and analysis

A 2.2 CRi Maestro in vivo fluorescence imaging system (CRi, Woburn, MA, USA) was used to acquire multispectral images. DsRed-expressing tumours were imaged using the green filter set (excitation 503 to 550 nm, emission 515 nm longpass). Acquisition settings were 550 to 800 nm in 10-nm steps. GFP-expressing tumours were imaged using the blue filter set (excitation 445 to 490 nm, emission 515 nm longpass). Acquisition settings were 500 to 720 nm in 10-nm steps. Exposure time was set automatically.

Determination of fluorescence signals was performed with Maestro software (2.22). For quantification a region of interest around the s.c. tumour was analysed by setting threshold as zero. The total signal intensity was divided by exposure time to allow comparison.

Immunohistochemistry

Immunohistochemical staining of paraffin slides was performed as described previously [25]. The following antibodies were used at room temperature: rabbit anti-PARP-1 (Cleaved p25, Epitomics, Burlingame, CA, 2294 © 2009 The Authors

Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
USA) at a dilution of 1:2000 for 3 hrs, biotin-labelled anti-rabbit IgG and HRP-conjugated streptavidine both at 0.5 μg/ml for 1 hr (Santa Cruz Biotechnology). Immunocomplexes were visualized with 3,3'-diaminobenzidine; slides were counterstained with haematoxyline and mounted with DePeX (all Dako, Glostrup, Denmark).

**Statistical analysis**

Statistical analysis was performed with SPSS 14.0 software (SPSS Inc. Chicago, IL, USA). An updated t-test including Levene testing for variances was used. A P-value < 0.05 was considered significant.

**Results**

**Stable expression of TRAIL at the cell surface of MSC upon lentiviral transduction**

Human MSC showed no morphological signs of apoptosis induction upon treatment with soluble TRAIL for 24 hrs, particularly no detachment of cells (Fig. 1A) and also no staining with annexin V (data not shown). We concluded that TRAIL could serve as a factor to be expressed in MSC in order to mediate an anti-tumour effect by tumour-integrating TRAIL-transgenic MSC.

**TRAIl-MSC** were generated through lentiviral transduction of MSC (for lentiviral construct see Fig. 1B). Western blot analyses of whole protein lysates revealed TRAIL expression at the size of the membrane bound protein (34 kD) over up to nine passages (Fig. 1C). Immunocytochemical analysis with two different antibodies raised against an extracellular domain of human TRAIL indicated presence of TRAIL at the cell surface (Fig. 1D). Incubation with control mouse IgG1 did not result in detectable staining (data not shown) and no TRAIL expression could be detected in WT-MSC (Fig. 1C, D). At passage 4 after transduction approximately 80% of the cells showed TRAIL expression in immunocytochemical analysis (data not shown).

Thus, lentiviral transduction of human MSC with TRAIL yielded an efficient and stable transgene expression with localization of TRAIL at the cell surface. Next we wanted to investigate whether lentiviral TRAIL expression altered the defining properties of MSC.

**Unaltered MSC characteristics in TRAIL-MSC**

We analysed TRAIL-MSC for their MSC characteristics as defined by consensus criteria [5]. Flow cytometric analyses revealed an identical immunophenotype for TRAIL-MSC and WT-MSC, i.e. CD14⁻, CD19⁻, CD34⁻, CD45⁻, HLA-DR⁻, CD73⁺, CD90⁺, CD105⁺ (Fig. 2A) and glycoporphin-A⁻, CD11c⁻, CD13⁻, CD29⁻, CD44⁻, CD166⁻ (data not shown). Following adipogenic and osteogenic differentiation induction, TRAIL-MSC showed multipotent differentiation with intracellular accumulation of lipid droplets and calcium deposition, respectively (Fig. 2B).

Conclusively, transgenic TRAIL expression in human MSC did not alter their defining MSC characteristics in comparison to
WT-MSC. As lentiviral transduction poses the risk of oncogene activation we analysed signs of malignant transformation in TRAIL-MSC.

**Lack of malignant transformation of TRAIL-MSC**

To assess the potential of malignant transformation of TRAIL-MSC we performed growth kinetics, soft agar assays and karyotype analysis with TRAIL-MSC and untransduced WT-MSC from the same donor starting at the time of transduction. TRAIL-MSC showed no changes in proliferation kinetics compared to WT-MSC (Fig. 2C). Neither soft agar colony formation nor karyotypic changes were observed in TRAIL-MSC (data not shown).

The transgenic expression of TRAIL may lead to apoptosis induction in transduced cells. However, we observed no increased annexin V-staining in TRAIL-MSC when compared to WT-MSC (Fig. 2D), indicating that transgenic TRAIL did not mediate apoptosis induction in TRAIL-MSC. These data were in accordance with the observed similar proliferation of TRAIL-MSC and WT-MSC (Fig. 2C).

Thus, lentiviral expression of TRAIL did neither result in signs of malignant transformation nor in apoptosis induction in human MSC. These data suggested that TRAIL-MSC may serve as a vehicle for tumour growth inhibition and we aimed to investigate their effect on TRAIL-sensitive CRC cells in vitro.

**Apoptosis induction in TRAIL-sensitive CRC cells through TRAIL-MSC in vitro**

As the CRC-cell line DLD-1 is reportedly sensitive to soluble TRAIL [26], we performed the initial analysis of the tumour-inhibiting capacity of TRAIL-MSC in this cell line. DsRed-DLD-1 cells were exposed to either TRAIL-MSC or WT-MSC in direct cocultures over 24 hrs in vitro. Occurrence of detached cells suggesting apoptosis was observed in cocultures with TRAIL-MSC but not with WT-MSC. These detached cells originated from DLD-1 cells, as shown by their DsRed expression (Fig. 3A). When cocultures containing TRAIL-MSC were supplemented with TRAIL-neutralizing antibody, no cell detachment was observed (Fig. 3A). Direct cell–cell contact was necessary for induction of detachment, as no relevant detachment of cells occurred upon incubation of DLD-1 cells with conditioned medium from TRAIL-MSC cultures (data not shown).

Proliferation of the respective cell subpopulations was assessed by determining the total cell numbers and the proportion of DsRed⁺ cells. In direct coculture with TRAIL-MSC over up to
72 hrs the absolute number of DsRed-DLD-1 cells decreased when compared to initially plated cell numbers. In contrast, a continuous increase of DsRed-DLD-1 cell numbers was seen in cocultures with WT-MSC (Fig. 3B). As DLD-1 cells did not express CD105 (data not shown) we examined CD105 expression on adherent cells to exclude cell fusion as a relevant contribution to the number of adherent DsRed cells. However adherent cells positive for CD105 showed no DsRed expression, i.e. uptake of DsRed by MSC did not skew the results (data not shown).

Cocultures with TRAIL-MSC resulted in apoptosis induction in DLD-1 cells since the detached cells stained positive with annexin V (Fig. 3C). This involved activation of the entire extrinsic apoptosis pathway since cleavage of PARP (116 kD), yielding an 85-kD fragment as well as cleavage of procaspase-8 (55 kD) and procaspase-3 (32 kD) into their active fragments of caspase-8 (41 and 18 kD) and caspase-3 (17 kD) was observed in cocultures of DsRed-DLD-1 with TRAIL-MSC. Cleavage of PARP and caspases was most prominent in detached cells (Fig. 3D). Apoptosis occurred solely in DLD-1 cells as detached cells were DsRed+ (Fig. 3A) and showed no expression of TRAIL (Fig. 3D). Induction
of apoptosis depended on the presence of TRAIL-MSC as in cocultures of DsRed-DLD-1 cells with WT-MSC neither relevant amounts of detached cells occurred (Fig. 3A) nor cleavage of PARP and procaspases was observed (Fig. 3D). Taken together, these data showed first, that TRAIL is functionally expressed in lentivirally transduced human MSC. Secondly, upon direct coculture, TRAIL-MSC induced apoptosis in TRAIL-sensitive DLD-1 cells resulting in a reduction of total tumour cell number. We suggested that direct interaction with ectopically TRAIL-expressing MSC may overcome TRAIL-resistance in CRC cells.

Apoptosis induction in TRAIL-resistant CRC cells through TRAIL-MSC in vitro

Next, we aimed to assess the anti-tumour activity of TRAIL-MSC in other CRC-cell lines. At first we analysed the response to soluble TRAIL in four CRC-cell lines in vitro. Upon TRAIL treatment, a reduction in the cell number below the pre-treatment values was observed for the cell lines HCT-15 and DLD-1. They were thus determined to be TRAIL-sensitive (Fig. 4A-a). The cell lines SW480 and HCT-8 showed continued cell proliferation upon TRAIL treatment and were therefore determined to be TRAIL-resistant (Fig. 4A-a). Growth inhibition occurred to some degree in TRAIL-resistant CRC-cell lines as demonstrated by the reduced cell numbers in comparison to the respective untreated controls at 24 hrs (Fig. 4A-a).

Subsequently, all four CRC-cells lines were directly cocultured with either WT-MSC or TRAIL-MSC. Western blot analyses revealed apoptosis induction as indicated by cleavage of PARP in TRAIL-sensitive CRC-cell lines as well as in the TRAIL-resistant CRC-cells lines SW480 and HCT-8 (Fig 4A-b). The response to TRAIL-MSC was further investigated in the TRAIL-resistant HCT-8 cell line. DsRed⁺ detached cells were observed after 24 hrs coculture of DsRed-HCT-8 cells with TRAIL-MSC but not in cocultures with WT-MSC (Fig. 4B). As for DLD-1 cells, detachment of DsRed⁺ cells was inhibited by a TRAIL-neutralizing antibody (Fig. 4B) and required direct cell–cell contact as no relevant detachment of HCT-8 cells occurred upon incubation with TRAIL-MSC conditioned medium (data not shown).

Coculture with TRAIL-MSC abolished the expansion of DsRed-HCT-8 cells although in contrast to DLD-1 cells the number of tumour cells at 72 hrs was not reduced in comparison to the initially plated cell numbers (Fig. 4C). The number of detached cells increased over the whole period in coculture with TRAIL-MSC while coculture with WT-MSC resulted in a rapid growth of DsRed-HCT-8 cells without detachment of cells (Fig. 4C). In cocultures with TRAIL-MSC detached cells stained with annexin V and cleavage of PARP, procaspase-8 and procaspase-3 was observed (Fig. 4D, E), supporting the notion of TRAIL-MSC induced apoptosis in HCT-8 cells. Detached cells were positive for DsRed indicating an exclusive induction of apoptosis in CRC cells (Fig. 4B). However, Western blot analysis of the detached cells showed a weak signal for TRAIL (Fig. 4E). As Ponceau S staining revealed equal protein loading for lysates of whole culture and detached cells we conclude that the faint TRAIL signal in detached cells indeed represented a very low level of TRAIL protein. The weaker signal for tubulin in detached cells in Fig. 4E despite equal protein loading can be explained by the reported [27] degradation of tubulin upon apoptosis. Conclusively, the very low level of TRAIL protein in lysates of detached cells could reflect a low degree of detachment of TRAIL-MSC as a bystander effect of apoptosis induction in adjacent HCT-8 cells. However, this low extent of detachment of TRAIL-MSC upon coculture with HCT-8 cells does apparently not interfere with the efficacy of apoptosis induction by TRAIL-MSC. As for DLD-1 cells, in cocultures of HCT-8 cells with WT-MSC no cleavage of PARP and procaspases was observed (Fig. 4E).

Thus, upon direct cell–cell contact in vitro, TRAIL-MSC are capable to induce apoptosis and to inhibit tumour cell growth not only in TRAIL-sensitive CRC-cell lines but also in two CRC-cell lines with proven resistance to soluble TRAIL. We therefore assumed that TRAIL-MSC may be capable of inhibiting tumour growth in vivo.

Reduction of tumour growth involving apoptosis induction by TRAIL-MSC in vivo

We generated s.c. xenografts of DsRed-DLD-1 cells mixed 4:1 with either TRAIL-MSC, GFP-MSC or WT-MSC, i.e. MSC amounting a proportion of 20% of the entire injected cell number. Tumour size was examined by in vivo fluorescence imaging of DsRed fluorescence intensity. After an identical decrease in fluorescence intensity until day 5 the signal intensities from DLD-1 xenografts mixed with GFP-MSC increased whereas intensities from xenografts with TRAIL-MSC remained low (Fig. 5A, B). This reflected a significant growth inhibition of DLD-1 xenografts by TRAIL-MSC compared to GFP-MSC (P = 0.006; confidence interval 350.3–1128.5) (Fig. 5B) and to WT-MSC (data not shown). A similar difference in tumour growth between xenografts containing WT-MSC and TRAIL-MSC containing xenografts was observed when size and weight of dissected tumours were compared (data not shown).

Next, we generated s.c. xenografts of the TRAIL-resistant DsRed-HCT-8 cell line mixed 4 : 1 with either TRAIL-MSC or WT-MSC. As measured by in-vivo imaging, HCT-8 xenografts containing TRAIL-MSC showed reduced growth compared to HCT-8 xenografts containing WT-MSC (Fig. 5C). Similar results were obtained when weight of dissected tumours were compared (data not shown). Thus, tumour-integrated TRAIL-MSC mediated inhibition of tumour growth not only in xenografts from TRAIL-sensitive DLD-1 cells but also in xenografts from TRAIL-resistant HCT-8 cells.

To prove apoptosis induction as the cause for reduced tumour growth we generated xenografts of DsRed-DLD-1 cells mixed with TRAIL-MSC in a proportion of 33:1, i.e. TRAIL-MSC comprising
3% of total cell number injected. This lower proportion was used since the lack of tumour growth with 20% TRAIL-MSC rendered histological examination impossible. A relevant tumour size was reached not earlier than day 7 and tumours were dissected on day 9. Histochemistry showed staining for cleaved PARP near stromal elements within the tumour (Fig. 5D) indicative for TRAIL-MSC induced apoptosis in CRC cells.

We concluded first, that human MSC retained functional expression of lentiviral TRAIL in vivo and second, that TRAIL-MSC can reduce tumour growth of CRC cells in vivo through induction of apoptosis. Given the published data on integration of MSC into tumours we next wanted to investigate the effect of systemically transplanted TRAIL-MSC on the growth of CRC xenografts.
Lack of effects of systemic TRAIL-MSC on growth of s.c. CRC xenografts

Dil-labelled TRAIL- or WT-MSC were injected into the tail vein in mice bearing s.c. GFP-DLD-1 xenografts. Tumour size was examined by in vivo fluorescence imaging.

In comparison to controls receiving no MSC a similar tumour growth occurred in mice receiving WT-MSC as well as in mice receiving TRAIL-MSC (Fig. 6A). No signs of toxicity were seen upon systemic transplantation of TRAIL-MSC. In particular no organ dysfunction and no formation of additional tumours were observed upon live observation of animals and macroscopic inspection after killing.

Ex vivo fluorescence imaging of whole dissected lungs showed strong signals in accordance with a pulmonary entrapment of the applied MSC (Fig. 6B). Lungs from animals which received no MSC (Fig. 6B) as well as dissected s.c. tumours from all animals showed no signals in whole organ fluorescence imaging (data not shown).

In cryosections of lungs from animals which received Dil-labelled TRAIL-MSC we saw large areas of red fluorescent cells confirming a pulmonary accumulation of MSC. Cryosection of s.c. tumours from these animals showed only a few Dil signals (Fig. 6C), indicating that only a very low percentage of MSC had integrated into s.c. tumours representing approx. 0.1% of total tumour cells.

We presumed that the lack of effects of systemic TRAIL-MSC on CRC growth was due to the low rate of tumour integration of TRAIL-MSC as a consequence of their pulmonary entrapment. To clarify this observation we evaluated the amount of tumour-integrated TRAIL-MSC required to inhibit tumour growth in our s.c. CRC-xenograft model.
Fig. 6 Lack of effects of systemic TRAIL-MSC on growth of s.c. CRC xenografts due to poor tumour integration in agreement with the need for a substantial proportion of tumour-integrated TRAIL-MSC to inhibit CRC-tumour growth in vivo. (A) Dil-labelled WT- and TRAIL-MSC were injected into tail vein of nude mice bearing s.c. GFP-DLD-1 xenografts on days 2, 4, 7, 10 and 15. Tumour sizes were quantified by imaging the GFP-fluorescence intensity of xenografts without MSC application (black square), with i.v. WT-MSC (green square) and with i.v. TRAIL-MSC (blue triangle). The total GFP-signal intensity divided by exposure time in ms is plotted. The total intensity / ms 2.5 hrs after generating xenografts was set 100%. Depicted as mean ± standard error of the mean (N = 3), except for tumours without MSC application (N = 1). (B) Lungs from mice with and without i.v. application of Dil-labelled WT- or TRAIL-MSC were dissected and imaged ex vivo to visualize Dil-labelled cells (red). The upper panel shows greyscale images. In the lower panel the respective fluorescence images are pictured. (C) Cryosections from lung and s.c. DLD-1 xenograft after i.v. application of Dil-labelled TRAIL-MSC. Nuclei were counterstained with DAPI. Fluorescence images are pictured as overlays of Dil (red) and DAPI (blue) fluorescence. Original magnification ×400. (D) S.c. mixed xenografts were generated with DsRed-DLD-1 cells and different amounts of WT-MSC (i.e. native or GFP-MSC) or TRAIL-MSC. Tumour size was examined by imaging the DsRed fluorescence intensity. Fluorescence signals of xenografts from DsRed-DLD-1 cells without MSC (black square), from DsRed-DLD-1 cells mixed with WT-MSC (green square) and TRAIL-MSC (blue triangle) were quantified. The total DsRed-signal intensity of tumours divided by exposure time in ms is plotted. The total intensity / ms 2.5 hrs after generating xenografts was set as 100%. Depicted as mean ± standard error of the mean (20% MSC N = 9; 10% N = 6; 3% N = 6; 1% N = 3; no MSC N = 4). Statistical relevance is only reached in comparison of 20% TRAIL-MSC with 20% WT-MSC (P = 0.005). Note that for 20% MSC the curve for WT-MSC is composed of data from xenografts with 20% GFP-MSC (N = 6) and with 20% WT-MSC (N = 3).
Requirement for a substantial proportion of tumour-integrated TRAIL-MSC to inhibit CRC-tumour growth in vivo

We generated s.c. mixed xenografts of DsRed-DLD-1 with different proportions of either WT-MSC (i.e. native or GFP-MSC) or TRAIL-MSC. Tumour size was examined by in vivo fluorescence imaging of tumour derived DsRed-signal and tumour size at the end of the experiment (day 17) was statistically compared.

Compared to xenografts without MSC, a proportion of 20% TRAIL-MSC reduced the tumour size considerably although this difference did not reach significance given the high standard deviations (P = 0.21; confidence interval –861.2 to 286.0). Without 10% TRAIL-MSC the tumour growth inhibition was less pronounced (P = 0.6) and 3% or 1% TRAIL-MSC had no effect on tumour growth (P = 0.9) in comparison to xenografts without MSC (Fig. 6D).

However, when the size of xenografts containing TRAIL-MSC were compared to xenografts containing WT-MSC (Fig. 6D) a significant difference was observed for 20% TRAIL-MSC versus 20% WT-MSC (P = 0.005; confidence interval 359.2–1190.9) and a still obvious difference for 10% TRAIL-MSC versus 10% WT-MSC (P = 0.18; confidence interval –214.5 to 1015.6) was seen.

This observation suggested that WT-MSC supported the growth of s.c. DLD-1 xenografts. Compared to xenografts without MSC, 20% WT-MSC increased tumour size at the end of the experiment considerably (P = 0.085; confidence interval –33.8 to 1058.7). A facilitated growth was also observed with 10% and 3% WT-MSC although less pronounced (P = 0.4 and 0.55, respectively). No differences in tumour size were observed between DsRed-DLD-1 xenografts mixed with untransduced MSC and xenografts mixed with GFP-MSC (data not shown).

Taken together, these results show that in this mixed xenograft model, a substantial proportion of TRAIL-MSC within the tumour was necessary for inhibition of tumour growth. Additionally, WT-MSC were able to support DLD-1 xenograft growth in this model depending on their frequency within the tumour.

Discussion

Our study originated from the reported TRAIL sensitivity of selected CRC-cell lines and our observation of a resistance of human MSC to soluble TRAIL. In our work on the sensitivity of MSC and CRC cells to soluble TRAIL we choose a concentration of 100 ng/ml soluble TRAIL. This represents 10% to 1% of the concentrations reached with recombinant TRAIL in clinical studies [28] but is comparable to doses used in other in vitro studies [13]. As further dose escalation does not result in altered response [13, 29] the results obtained in our study are regarded representative for the assessment of TRAIL sensitivity.

We show that transduction of human MSC with a third generation lentiviral construct comprising a self-inactivating 3’ LTR and the cDNA of TRAIL does not change defining MSC characteristics. Interestingly, transgenic TRAIL did not exert pro-apoptotic effects on MSC. An explanation consists of a low sensitivity of MSC for TRAIL as described for other non-malignant cells. Importantly, no signs of malignant transformation were observed for lentivirally transduced MSC in vitro and in vivo.

Based on our data we suggest that the lasting transmembraneous expression of TRAIL in TRAIL-MSC is essential for a relevant anti-tumour activity. Further research is warranted to evaluate whether a higher level of expression may facilitate clinical applications.

The four CRC-cell lines used in our study could be divided in lines sensitive and resistant to soluble TRAIL. Strikingly, our data show that TRAIL-MSC could overcome resistance to soluble TRAIL in two specific cell lines through induction of apoptosis. This observation may be explained by direct cell–cell contact which might either exert higher persistent concentrations of TRAIL or additional pro-apoptotic inter-cellular communications compared to short-lived soluble TRAIL.

A recent work [15] reported anti-tumour activity of MSC-expressed trimeric TRAIL (stTRAIL). This secreted form of TRAIL could result in a broader radius of action within the tumour compared to membrane-expressed TRAIL. It would be interesting whether stTRAIL could help to overcome resistance to soluble TRAIL in our CRC cell model.

MSC with transgenic expression of anti-tumour genes have the potential to exert a strong inhibitory effect on tumour growth (reviewed in [2–4]) in models of systemic application [7, 30], in mixed s.c. xenografts [6] or by intratumoral injection [17]. In our view the systemic application of MSC as well as the mixed s.c. xenograft is better suited than intratumoral injection as the latter entails local mechanical damage probably skewing the results. Albeit we observed a strong effect in mixed xenografts, a systemic effect of TRAIL-MSC was not seen in our model. Our results suggest that this results from a limited integration of TRAIL-MSC into s.c. DLD-1-tumours due to their pulmonary entrapment. A pulmonary entrapment of systemically applied human MSC [31–34] but also of human tumour cells [35] has been reported. It has to be pointed out, that in most of those studies which demonstrated an anti-tumour effect of systemically applied transgenic MSC pulmonary tumour models were used [30, 36, 37]. Thus, such pulmonary entrapment of MSC may explain the increased anti-tumour effect of systemically applied transgenic MSC in
pulmonary tumour models compared to s.c. tumour models. However, tumour integration [7, 38, 39] and even proliferation [8] of systemically applied MSC was seen in s.c. tumours in a few studies. To date, no obvious explanation exists for these differential observations. The observed clinical effects of systemically applied MSC in patients [40–44] can be seen as an indication that a pulmonary entrapment as observed in mice may not be relevant in human beings. This raises the question whether further animal studies will help to clarify the relevance of pulmonary entrapment of MSC in human beings. Our data point out that the net effect of tumour-integrated MSC may depend on their frequency within the tumour. The results in our DLD-1 model suggest that a proportion of TRAIL-MSC exceeding 3% of total tumour cells may be relevant.

For native/WT-MSC we observed a supportive effect on tumour growth in our model of DLD-1 xenografts. Whether this is representative or just reflects a cell line-specific effect remains open. Similar observations have been reported previously in other cell models [38, 45–47] and also specifically for CRC-cell lines [48].

Taken together, our results suggest that TRAIL-MSC generated by lentiviral gene transfer may provide a safe approach for a novel anti-tumour therapy in CRC. However, a relevant anti-tumour activity may require a substantial intratumoral presence of transplanted TRAIL-MSC and has to be weighted against a potential tumour growth-supporting effect of MSC. Thus, our study warrants further investigation on the use of TRAIL-MSC as vehicles of tumour therapy perspective including pilot clinical trials.

Acknowledgements

We are grateful to the donors who gave consent for the use of their bone marrow aspirates. We thank D. Wand, Ph.D., Department of Human Genetics, Medical Faculty of the Martin-Luther-University Halle-Wittenberg for performing the karyotype analysis. The study was supported in part by grants from the Federal State of Saxonia-Anhalt and the German Ministry of Education and Research through the Wilhelm-Roux-Program at the Medical Faculty of the Martin-Luther-University Halle-Wittenberg (1/10 3/15 6/08, 3/27) (L.P.M.) and the European Union through BioService Halle GmbH (J.L.).

Declaration of interest

None of the authors has to declare a commercial interest related to the contents of the study.

References

1. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008; 134: 1296–310.
2. Abdoody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008; 15: 739–52.
3. Corsten MF, Shah K. Therapeutic stem cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol. 2008; 9: 376–84.
4. Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells. 2008; 26: 1387–94.
5. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315–7.
6. Studeny M, Marini FC, Champlin RE et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon- beta delivery into tumors. Cancer Res. 2002; 62: 3603–8.
7. Kucerova L, Altanerova V, Matuskova M et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007; 67: 6304–13.
8. Hung SC, Deng WP, Yang WK et al. Mesenchymal stem cell targeting of microscopic stem cell tumor growth-supporting effect of MSC. Thus, our study warrants further investigation on the use of TRAIL-MSC as vehicles of tumour therapy perspective including pilot clinical trials.
sharp transition from division to development in culture. Stem Cells. 2008; 26: 193–201.

21. Chan J, O’Donoghue K, de la Fuente J et al. Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem Cells. 2005; 23: 93–102.

22. Dull T, Zufferey R, Kelly M et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998; 72: 8463–71.

23. Sukehara P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82: 1107–12.

24. Lois C, Hong EJ, Pease S et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002; 295: 868–72.

25. Mueller T, Voigt W, Simon H et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res. 2003; 63: 513–21.

26. Zhang L, Gu J, Lin T et al. Mechanisms involved in development of resistance to adenosine-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther. 2002; 9: 1262–70.

27. Moss DK, Lane JD. Microtubules: orgotten players in the apoptotic execution phase. Trends Cell Biol. 2006; 16: 330–8.

28. Ling J, Herbst RS, Mendelson DS et al. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J Clin Oncol (Meeting Abstracts). 2006; 24: 3047.

29. Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104: 155–62.

30. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004; 96: 1593–603.

31. Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003; 108: 863–8.

32. Bentzon JF, Stenderup K, Hansen FD et al. Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene. Biochem Biophys Res Commun. 2005; 330: 633–40.

33. Gao J, Dennis JE, Muzic R et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001; 169: 12–20.

34. Hakkarainen T, Sarkioja M, Lehenkari P et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther. 2007; 18: 627–41.

35. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther. 2007; 15: 660–5.

36. Stolf-Khalili MA, Rivera AA, Mathis JM et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. 2007; 105: 157–67.

37. Kusuhara M, Xin H, Hoshino K et al. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther. 2007; 14: 894–903.

38. Karmouh AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449: 557–63.

39. Khakoo AY, Pati S, Anderson SA et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 2006; 203: 1235–47.

40. Christopeit M, Schendel M, Foll J et al. Marked improvement of severe progres-